Clinical Trial ProgressManagement has reported higher compliance than in the previous trial and patients have good disease control, indicating a chance for positive outcomes in the '204 trial.
Financial PositionSpruce Biosciences ended 2Q24 with $69.7M in cash and cash equivalents, expected to be sufficient to fund operations through the end of 2025 based on the company's current strategic plan.
Market OpportunityTildacerfont could be the second CAH drug to market, tapping into a rare disease market with 20,000 to 30,000 patients in the U.S. and 250 new patients identified annually via newborn screening.